Rhythm Pharmaceuticals (RYTM) Assets Average (2017 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Assets Average of $461.3 million for Q1 2026, up 18.43% year-over-year from $389.5 million in Q1 2025, and down 6.54% quarter-over-quarter from $493.5 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Assets Average (2017 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Assets Average for 10 consecutive years, with $461.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 18.43% year-over-year to $461.3 million; the TTM figure through Mar 2026 stood at $461.3 million (up 18.43% YoY), while the FY2025 annual figure was $436.2 million, up 20.34% from the prior year.
- Assets Average slipped to $461.3 million in Q1 2026 per RYTM's latest filing, from $493.5 million in the prior quarter.
- Across five years, Assets Average topped out at $493.5 million in Q4 2025 and bottomed at $281.2 million in Q2 2022.
- Historically, Assets Average has averaged $365.1 million across 5 years, with a median of $364.1 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average slumped 30.61% — and 2025, when it surged 31.72%.
- Rhythm Pharmaceuticals' Assets Average stood at $386.0 million in 2022, then decreased by 11.03% to $343.5 million in 2023, then gained by 10.03% to $377.9 million in 2024, then soared by 30.59% to $493.5 million in 2025, then dropped by 6.54% to $461.3 million in 2026.
- Business Quant data shows RYTM's Assets Average at $461.3 million in Q1 2026, $493.5 million in Q4 2025, and $439.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 439.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 439.79 Mn |
| Mar 31, 2026 | 461.26 Mn |
| Dec 31, 2025 | 493.54 Mn |
| Sep 30, 2025 | 439.80 Mn |
| Jun 30, 2025 | 379.71 Mn |
| Mar 31, 2025 | 389.48 Mn |
| Dec 31, 2024 | 377.92 Mn |
| Sep 30, 2024 | 372.71 Mn |
| Jun 30, 2024 | 320.25 Mn |
| Mar 31, 2024 | 295.70 Mn |
| Dec 31, 2023 | 343.47 Mn |
| Sep 30, 2023 | 332.07 Mn |
| Jun 30, 2023 | 327.81 Mn |
| Mar 31, 2023 | 364.08 Mn |
| Dec 31, 2022 | 386.05 Mn |
| Sep 30, 2022 | 333.64 Mn |
| Jun 30, 2022 | 281.25 Mn |
| Mar 31, 2022 | 307.17 Mn |
| Dec 31, 2021 | 342.67 Mn |
| Sep 30, 2021 | 372.11 Mn |